ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.331,39
0,00%
S&P 500
5.469,30
0,00%
US Dollar vs BRL
5,505
0,97%
Bitcoin
61.440,70
-0,60%
Brent Oil
84,32
0,16%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Gain Therapeutics Inc (GANX)

  7. Gain Therapeutics Inc (GANX) Notícias

GANX

Gain Therapeutics (GANX)

Gain Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GANX
DataHoraFonteTítuloCódigoCompanhia
25/06/202408:00GlobeNewswire Inc.Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceNASDAQ:GANXGain Therapeutics Inc
17/06/202409:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GANXGain Therapeutics Inc
14/06/202417:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GANXGain Therapeutics Inc
13/06/202422:00GlobeNewswire Inc.Gain Therapeutics Announces Pricing of $11.0 Million Public OfferingNASDAQ:GANXGain Therapeutics Inc
13/06/202417:44GlobeNewswire Inc.Gain Therapeutics Announces Proposed Public OfferingNASDAQ:GANXGain Therapeutics Inc
30/05/202408:00GlobeNewswire Inc.Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024NASDAQ:GANXGain Therapeutics Inc
14/05/202417:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GANXGain Therapeutics Inc
14/05/202408:30GlobeNewswire Inc.Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate UpdateNASDAQ:GANXGain Therapeutics Inc
24/04/202410:25GlobeNewswire Inc.Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
08/04/202410:25GlobeNewswire Inc.Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial OfficerNASDAQ:GANXGain Therapeutics Inc
01/04/202410:25GlobeNewswire Inc.Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical OfficerNASDAQ:GANXGain Therapeutics Inc
26/03/202409:00GlobeNewswire Inc.Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate UpdateNASDAQ:GANXGain Therapeutics Inc
15/03/202415:30GlobeNewswire Inc.Gain Therapeutics to Present at Public Ventures Discovery DayNASDAQ:GANXGain Therapeutics Inc
05/03/202410:00GlobeNewswire Inc.Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
27/02/202416:00GlobeNewswire Inc.Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
14/02/202414:29GlobeNewswire Inc.Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst InsightNASDAQ:GANXGain Therapeutics Inc
06/02/202411:56GlobeNewswire Inc.UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
06/02/202410:00GlobeNewswire Inc.Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
31/01/202410:00GlobeNewswire Inc.Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational UpdateNASDAQ:GANXGain Therapeutics Inc
02/01/202418:09Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GANXGain Therapeutics Inc
02/01/202410:00GlobeNewswire Inc.Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024NASDAQ:GANXGain Therapeutics Inc
02/01/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GANXGain Therapeutics Inc
19/12/202318:52Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:GANXGain Therapeutics Inc
01/12/202310:00GlobeNewswire Inc.Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis ModelNASDAQ:GANXGain Therapeutics Inc
29/11/202310:00GlobeNewswire Inc.Gain Therapeutics to Participate in AI Driven Drug Discovery SummitNASDAQ:GANXGain Therapeutics Inc
24/11/202315:01GlobeNewswire Inc.Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment OptionNASDAQ:GANXGain Therapeutics Inc
21/11/202310:54GlobeNewswire Inc.Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and WarrantsNASDAQ:GANXGain Therapeutics Inc
14/11/202309:00GlobeNewswire Inc.Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:GANXGain Therapeutics Inc
04/10/202308:00GlobeNewswire Inc.Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s DiseaseNASDAQ:GANXGain Therapeutics Inc
25/09/202317:05GlobeNewswire Inc.Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023NASDAQ:GANXGain Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:GANX

Seu Histórico Recente

TSXV
CPL
Copper Lake Resources
COIN
MOGETH
Mog Coin
NYSE
CCIV.WS
Churchill Capital Corp IV
CSE
DVR
Deveron UAS
LSE
AH53
Nationwde.26
LSE
81BO
Swedbank 5.75%
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados